GlobeNewswire by notified

Galapagos creates new subscription right plan

Share

Mechelen, Belgium;13 January 2022, 22.01CET;regulated information – GalapagosNV (Euronext & NASDAQ: GLPG) announced today that its supervisory board created 30,000 subscription rights under a new employee subscription right plan.

On 13 January 2022, the supervisory board of Galapagos approved a subscription right plan intended for an employee of a subsidiary of the Company (not intended for members of the management board of the Company), within the framework of the authorized capital. Under this subscription right plan, 30,000 subscription rights were created (subject to acceptance). The subscription rights have an exercise term of eight years as of the date of the offer and an exercise price of €46.18 (the closing price of the Galapagos share on Euronext Amsterdam and Brussels on the day preceding the date of the offer). Further details are available on the Galapagos website.

Galapagos’ total share capital currently amounts to €354,582,005.11; the total number of securities conferring voting rights is 65,552,721, which is also the total number of voting rights (the “denominator”), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights to subscribe to not yet issued securities conferring voting rights is (i) 8,579,287 subscription rights under several outstanding employee subscription right plans, which equals 8,579,287 voting rights that may result from the exercise of those subscription rights, and (ii) one subscription right issued to Gilead Therapeutics to subscribe for a maximum number of shares that is sufficient to bring the shareholding of Gilead and its affiliates to 29.9% of the actually issued and outstanding shares after the exercise of the subscription right. This excludes the 30,000 subscription rights of the newly issued subscription right plan, which were created subject to acceptance. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

About Galapagos
Galapagos NV discovers, develops, and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. More information at www.glpg.com.

Contact
Investors:
Sofie Van Gijsel
Head of Investor Relations
+1 781 296 1143

Sandra Cauwenberghs
Director Investor Relations
+32 495 58 46 63
ir@glpg.com

Media:
Marieke Vermeersch
Head of Corporate Communication
+32 479 490 603
communications@glpg.com

Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates16.8.2022 09:01:00 CEST | Press release

– ColoAlert to be marketed through Dante’s extensive database and sold via its region-specific, ecommerce websites – BERKELEY, Calif. and MAINZ, Germany and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz'' or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, and Dante Genomics, a global leader in genomics and precision medicine, announced today the formal commencement of ColoAlert’s consumer commercial program in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use, at-home detection test for colorectal cancer (CRC) currently being commercialized across Europe and select international markets. With the ColoAlert test CE-IVD certified and patient collection kit CE marked to the latest IVDR requirements, ColoAlert will now be marketed through Dante’s extensive database and sold via Dante’s, region-specific, ecommerce websites. “This is

Cody Patrick Named OEM Direct Sales Manager for Nikkiso Clean Energy and Industrial Gases Group16.8.2022 09:01:00 CEST | Press release

TEMECULA, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is pleased to announce that Cody Patrick has been named OEM Direct Sales Manager for Nikkiso ACD, a part of the Cryogenic Pumps unit of Nikkiso’s Clean Energy & Industrial Gases Group. Cody is a graduate of Texas A&M College of Engineering’s Industrial Distribution program. The combination of his education and experience with Cryogenic pumps for the industrial gases market, make him well suited to assist with growing the U.S. market. He will manage and develop business strategies and opportunities as well as assist with the development of training and educational programs for the Group’s clients. Cody will be based in Houston and report to Ian Guthrie, Business Line Manager for the Group’s Cryogenic Pumps unit. “Given Cody’s enthusiasm and understanding of the cryogenic pumps market we are excited t

Ahold Delhaize share buyback update16.8.2022 08:00:00 CEST | Press release

Zaandam, the Netherlands, August16, 2022 – Ahold Delhaize has repurchased 254,408 of its common shares in the period from August 8, 2022 up to and including August 12, 2022. The shares were repurchased at an average price of € 27.21 per share for a total consideration of € 6.9 million. These repurchases were made as part of the € 1 billion share buyback program announced on November 15, 2021. The total number of shares repurchased under this program to date is 20,621,088 common shares for a total consideration of € 561.6 million. Download the share buyback transactions excel sheet for detailed individual transaction information from https://www.aholddelhaize.com/en/investors/share-buyback-programs/2022/ This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.

Sanionas Kv7-program för epilepsi avanceras till leadoptimering16.8.2022 08:00:00 CEST | Pressemelding

PRESSMEDDELANDE 16 augusti 2022 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling, meddelar idag att bolaget har avancerat sitt lovande Kv7-program för epilepsi till fasen leadoptimering – den sista fasen av läkemedelsupptäckt innan en klinisk kandidat väljs ut. Thomas Feldthus, VD: ”Vi tror att vi har löst knäckfrågorna för att utveckla nästa generation av läkemedelskandidater av den här klassen, och vi ser en betydande potential att ta fram nya banbrytande epilepsibehandlingar. Finansiellt kan uppsidan vara avsevärd, att döma av vissa viktiga läkemedelsavtal som nyligen slutits på Kv7-området.” Miljontals människor runt om i världen påverkas i dag av epilepsi, en sjukdom som kännetecknas av återkommande krampanfall. Det medicinska behovet är stort, eftersom omkring 30 procent av patienterna inte svarar på behandling med konventionella läkemedel mot epilepsi. Läkemedel mot kramper kan desutom ha funktionshämmande biverkningar, som ofta måste minimeras genom no

Saniona progresses its Kv7 epilepsy program into Lead Optimization16.8.2022 08:00:00 CEST | Press release

PRESS RELEASE August 16, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that it has progressed its promising Kv7 epilepsy program into the Lead Optimization Phase, which is the last drug discovery phase before potential selection of a clinical candidate. Thomas Feldthus, CEO: “We believe that we have cracked the main challenges for making the next generation drug candidates of this class and see significant potential for delivering new breakthrough epilepsy treatments. The financial upside could be substantial based on very significant pharma deals recently executed in the Kv7 field”. Epilepsy, characterized by recurrent seizures, currently affects millions of people worldwide. There is a significant medical need as approximately 30% of patients are insensitive to treatment by conventional epilepsy medicines. Furthermore, anti-seizure therepy may cause disabling side effects and often require careful dose adjustment to minimize these. Kv7 ion ch